News Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Nov 21, 2017Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, has received...
- Nov 10, 2017Executes Material Transfer Agreement with Yissum for Two Synthetic Agonists Synthesized by Professor Raphael Mechoulam
Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based treatments, executed a non-exclusive material...
- Nov 9, 2017- Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT -
Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based treatments, today reported financial results for...
- Nov 7, 2017Presentation at the Biotech & Money Inv€$tival Showcase to Be Held on November 14, 2017 at 4:15PM CET
Josh Blacher, Chief Financial Officer of Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of...
- Nov 2, 2017
Therapix Biosciences Ltd. (NASDAQ: TRPX), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based drugs, announced today that it will host a...